Bicara Therapeutics BCAX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $112M+107% | $94.9M+110% | $85.9M— | ||
| $35.8M+56.4% | $30.51M+62.5% | $29.13M+92.4% | $26.19M+102% | $22.88M— | ||
| $174.06M+60.0% | $155.6M+88.9% | $141.12M+103% | $121.07M+108% | $108.8M— | ||
| -$174.06M-60.0% | -$155.6M-88.9% | -$141.12M-103% | -$121.07M-108% | -$108.8M— | ||
| $16.94M+1.3% | $17.87M+22.6% | $19.95M— | $18.71M— | $16.73M— | ||
| -$157.12M-70.6% | -$137.73M-103% | -$121.17M-104% | -$102.36M-57.9% | -$92.08M— | ||
| $197K-23.6% | $217K+16.0% | $350K— | $310K— | $258K— | ||
| -$157.32M-70.4% | -$137.95M-103% | -$121.52M-104% | -$102.67M-58.3% | -$92.33M-61.8% | ||
| -$2.78— | -$2.53— | —— | —— | —— | ||
| -$173.93M-59.9% | -$155.5M-88.9% | -$141.04M-103% | -$121M— | -$108.74M— | ||
| -$174.06M-60.0% | -$155.6M-88.9% | -$141.12M-103% | -$121.07M-108% | -$108.8M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Bicara Therapeutics profitable?
- Bicara Therapeutics is not currently profitable: it reported a net loss of $157.3M over the trailing twelve months.
- What is Bicara Therapeutics's earnings per share?
- Bicara Therapeutics's diluted EPS over the trailing twelve months is $-2.78.
- Where does Bicara Therapeutics's income statement data come from?
- Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.